Share your research data

This research addresses in-office preparation and use of buffered lidocaine with epinephrine. Our multidisciplinary collaboration evaluates the stability, sterility, antimicrobial effectiveness, and safe compounding protocols for these preparations. The findings contribute significantly to the growing body of evidence supporting patient safety, regulatory compliance, and clinical efficiency in dermatologic surgery settings. Importantly, this study helps clarify the scientific rationale behind the recently developed monograph and joint position statements from leading dermatologic societies (American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery, and American Society for Mohs Surgery). Our data support assigning a beyond-use date (BUD) of 7 days under refrigeration and 24 hours at room temperature, in alignment with the updated U.S Pharmacopeial (USP) General Chapter <797> standards.

Data to the manuscript entitled "Sex-specific but not urbanisation-related behavioural differences in a wolf spider, Pardosa alacris"

The G-protein coupled receptor 75 (GPR75) emerged as a promising therapeutic target for treating diet-induced-obesity. Loss-of-function mutations of GPR75 in humans are associated with reduced body mass index (BMI). Also, Gpr75 deficient mice are protected from diet induced obesity (DIO). Here, we generated genetically-modified mice that enables us to selectively delete or reactivate Gpr75 in a Cre-dependent manner. Loss of Gpr75 in vGlut2+ glutamatergic neurons (Gpr75vGlut2-KO) results in a protection against high fat diet (HFD)-induced weight gain, whereas loss of Gpr75 in GABAergic neurons show no protection against DIO. Furthermore, male Gpr75vGlut2-KO mice have reduced food intake on HFD without a change in energy expenditure. Reactivation of Gpr75 only in vGlut2-expressing cells in a Gpr75 null mouse (Gpr75TB) completely rescues the HFD-induced weight gain, whereas reactivation in GABAergic cells has no effect on body weight or adiposity. These complementary results demonstrate the importance of glutamatergic neurons in GPR75’s regulation of food intake and protection from obesity.

Raw data including responses from 200 participants (100 musicians) on perceived emotion, as well as valence and arousal ratings, for 116 musical stimuli. The dataset also includes responses to the Beck Anxiety Inventory (BAI), Beck Depression Inventory (BDI), and a musical background questionnaire. The dataset further includes the musical stimuli selected and validated for the Musical Emotion Evaluation Test (MEET), supporting transparency, replication, and reuse.

This dataset includes raw and processed measurements examining how modulation of intracellular cholesterol alters the efficacy of FDA-approved siRNA therapeutics. Data are structured according to experimental variables, including cell model, cholesterol manipulation strategy, siRNA treatment, and target suppression quantified at both the mRNA and protein levels.

This dataset presents the empirical analysis materials from the paper "Does short selling of customers affect analysts' forecasts for suppliers?"

Supplementary files for the manuscript: How Global Energy Efficiency Varies from the Perspective of 136 Countries: A Spatial‒Temporal Analysis Considering Game Crossings.

Research data related to the ​​Department of Psychology of the University of Milano - Bicocca

Data collection was based on two online surveys, set-up via the online tool Netigate, and gathered feedback from 199 teachers and 368 pupils regarding education at Swedish riding schools as perceived by teachers and pupils.

We defined an antidepressant potentiation treatment with add-on low-dose interleukin 2 (IL-2). IL-2 is a T-cell growth factor which has proven anti-inflammatory efficacy in autoimmune conditions, increasing thymic production of naïve CD4 + T cells, and possibly correcting the partial T cell defect observed in mood disorders. We performed a single-center, randomised, double-blind, placebo-controlled phase II trial evaluating the safety, clinical efficacy and biological responses of low-dose IL-2 in depressed patients with major depressive (MDD) or bipolar disorder (BD). 36 consecutively recruited inpatients at the Mood Disorder Unit were randomised in a 2:1 ratio to receive either aldesleukin (12 MDD and 12 BD) or placebo (6 MDD and 6 BD). Active treatment significantly potentiated antidepressant response to ongoing SSRI/SNRI treatment in both diagnostic groups, and expanded the population of T regulatory, T helper 2, and percentage of Naive CD4+/CD8 + immune cells. Changes in cell frequences were rapidly induced in the first five days of treatment, and predicted the later improvement of depression severity. No serious adverse effect was observed. This is the first randomised control trial (RCT) evidence supporting the hypothesis that treatment to strengthen the T cell system could be a successful way to correct the immuno-inflammatory abnormalities associated with mood disorders, and potentiate antidepressant response.